Chumsri Saranya, Phatak Pornima, Edelman Martin J, Khakpour Nazanin, Hamburger Anne W, Burger Angelika M
Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA.
Cancer Genomics Proteomics. 2007 May-Jun;4(3):165-74.
The concept of individualized cancer chemotherapy emerged three decades ago from the observation that a small fraction of cells in primary tumors can form colonies in soft agar similar to stem cells of the hematopoietic system. In a series of retrospective and prospective clinical studies, clonogenic tumor growth and effects of anticancer agents on the putative cancer stem cells were assessed as predictive factors. The results of these trials showed that clonogenic growth is associated with poor outcome and drug resistance. Recent breakthroughs enabling isolation and the molecular classification of cancer stem cells have renewed interest in cancer stem cells as a therapeutic target. Here, we provide a current overview of cancer stem cell biology and highlight possibilities for targeted intervention with existing and novel experimental anticancer agents.
个性化癌症化疗的概念始于三十年前，当时观察到原发性肿瘤中的一小部分细胞能够在软琼脂中形成集落，类似于造血系统的干细胞。在一系列回顾性和前瞻性临床研究中，克隆源性肿瘤生长以及抗癌药物对假定的癌症干细胞的作用被评估为预测因素。这些试验的结果表明，克隆源性生长与不良预后和耐药性相关。最近能够实现癌症干细胞分离和分子分类的突破，重新激发了人们将癌症干细胞作为治疗靶点的兴趣。在此，我们提供癌症干细胞生物学的当前概述，并强调使用现有和新型实验性抗癌药物进行靶向干预的可能性。
